Can you do ketamine and TMS at the same time?

Clinical sections reviewed by Dr Christopher Gauci, MD MRCS(Ed) EDAIC

Two doctors discussing an MRI film by a window

Yes, some clinics give ketamine and TMS together, either in the same sitting or as two courses running across the same weeks. The data behind it is still small. A 2023 review in Frontiers in Neuroscience found 11 published reports, most of them single cases or reviews of past clinic records (Dębowska and colleagues, 2023).

We do not offer TMS. The week in Malta is built around ketamine-assisted sessions, and a TMS course you are having elsewhere is one of the things our two doctors read before anything is planned.

Can you do ketamine and TMS at the same time?

It has been done in three ways. TMS, short for transcranial magnetic stimulation, sends magnetic pulses from a coil held against the head into the cortex under it. The standard US course runs four to six weeks; with ketamine, a change can show after the first dose (Dębowska and colleagues, 2023).

In the same sitting. TMS runs while the ketamine dose goes in. Most of the reports in the 2023 review used this form (Dębowska and colleagues, 2023).

In parallel. Both courses run in the same weeks, in separate sessions.

One after the other. Ketamine follows a course of TMS that did not bring the hoped-for change.

The review found no reports of harm from the combination, which across eleven mostly single cases is not established safety. The care is about this: ketamine raises excitability in the motor cortex, a reason for caution when it goes in at the same moment as excitatory stimulation, and the pair can mean stronger side effects. A preliminary study found no such rise in the prefrontal cortex, the area a standard depression course aims at, and on that reading the review says pulses there during an infusion could be given without the seizure risk. Courses given at separate times the review treats as safe in their own right, with care. The combination is still experimental, so the authors ask for a consent conversation that says so, and they list the cautions the two share: seizures or epilepsy in the past, anything metal or electronic in the head, and uncontrolled high blood pressure (Dębowska and colleagues, 2023).

If a clinic offers you the combination, write down which of the three forms it is: pulses during the dose, two courses in the same weeks, or ketamine started after a course of TMS. They do not carry the same caution.

Why clinics combine them

The reasoning rests on neuroplasticity, the brain’s ability to form and change connections. Both treatments appear to push it in the same direction, through the glutamate system, and the 2023 review sets out the case for the two reinforcing each other (Dębowska and colleagues, 2023). How ketamine acts on the brain’s glutamate system has its own page.

The idea clinics describe goes like this: ketamine opens a short window in which connections change more easily, and TMS, aimed at one area of the brain, makes use of that window. It is a working explanation. The same review notes that no experiment has yet looked at what happens in the brain when people have both (Dębowska and colleagues, 2023), so the window idea explains why clinics combine them and still has to be tested.

There is a practical reason too. The two treatments work on different clocks, one judged from the first dose and one over a course of weeks, so a clinic that offers both can put them in a single plan. The 2019 clinic series also reported that the ketamine allowed stronger TMS pulses than people would otherwise have tolerated (Best and colleagues, 2019).

What the reasoning means for one person depends on what they have already tried and how they responded. Before any consultation about the combination, it is worth writing out the order: each treatment, when it started and stopped, and what changed while you were on it.

What the evidence shows so far

Clinics use the combination for depression that has not lifted with one treatment alone, and the reports differ a lot in who was treated and how (Dębowska and colleagues, 2023).

By September 2023 the review had found 11 papers, mostly single-person case reports and retrospective reviews of clinic records, with no comparison group and no randomised trial among them (Dębowska and colleagues, 2023). Nine of the eleven come from one private US clinic and the same lead author, so the file reads as the experience of one centre rather than eleven independent signals. The stimulation there differed too: low-frequency pulses at 1 Hz aimed at the anterior cingulate cortex, which damps activity, while a standard depression course uses high-frequency pulses over the dorsolateral prefrontal cortex, which raises it (Dębowska and colleagues, 2023).

The 2019 report from that clinic is a follow-up of its own earlier series: the same 28 people, scored by a clinician in the clinic that treated them, no comparison group, and the improvement still there two years later (Best and colleagues, 2019).

A later study set the combination against TMS on its own. In a Florida clinic, 66 people had 36 sessions of deep TMS plus six ketamine infusions over nine weeks, 169 the same TMS alone: response 80.3% against 76.9%, remission 43.4% against 39.6%, no significant difference between the groups, and the authors read it as no added benefit from the infusions; the groups were not randomised (Shanok and colleagues, Psychopharmacology, 2024). So the two answer the same question and disagree, on different protocols: inhibitory pulses in the older series, excitatory here.

In the Canadian series, 4 of 21 people who had not responded to TMS responded to six ketamine infusions given afterwards, and 2 went into remission (Payette and colleagues, 2023). What the trials of ketamine on its own found is set out separately. If you are holding your own case against these reports, the question that helps is which of them you resemble, and on which protocol.

Order and timing

The authors of the 2023 review suggest that running full courses of both in parallel, but not at the same moment, is the likely way to get the benefit, and they present it as a hypothesis still to be tested rather than a sequence any guideline sets out (Dębowska and colleagues, 2023).


Ketamine is not a first-line treatment for depression, and it is not the last resort it is sometimes described as either.

The usual sequence starts with psychotherapy, an antidepressant or both, then a change of drug or an added medication if the first does not work. When two antidepressants at a proper dose, taken long enough to judge, have failed in the same episode, the depression is described as treatment-resistant.

Most of the research was done in this group, and it is the main indication for esketamine, the licensed nasal-spray form. In the EU, esketamine is also licensed for short-term use in a depressive psychiatric emergency. Ketamine given by infusion is not licensed for depression at all: it is prescribed off-label, on the treating doctor’s clinical judgement and responsibility. That judgement can extend to people who have not tried two antidepressants, but the evidence there is thinner, and patients should be told so. What does not change with the setting is the requirement for a proper psychiatric assessment first.

At that point the realistic choices are another antidepressant or an augmentation strategy, ketamine, repetitive transcranial magnetic stimulation, electroconvulsive therapy, and for some people an intensive or residential programme instead of weekly outpatient care.

These options do not sit on one scale. Electroconvulsive therapy has the strongest evidence in severe depression and the heaviest burden. Transcranial magnetic stimulation is non-invasive with a lighter side-effect profile and a slower course. Ketamine acts fastest and does not hold on its own without a plan for what comes after.

What counts as a proper dose taken long enough is worth pinning down, because mislabelling here is the most common reason someone gets called treatment-resistant when they are not. It means a therapeutic dose, taken consistently, generally for several weeks at target dose.

Someone who stopped an antidepressant early because of side effects, or never reached a therapeutic dose, has a different problem with a different answer, and should say so during assessment.

Checked for medical accuracy by Dr Christopher Gauci, MD MRCS(Ed) EDAIC on 1 October 2026. The check covers this section. Everything else on the page is written by our editorial team and verified against primary sources.

If you have had TMS already, two dates are worth having written down before anyone plans a sequence for you: when the course ended, and when you last noticed a change while you were on it.

If you are mid-way through TMS

Most clinics that offer the combination run both treatments in-house. If your TMS is with another provider, the information has to travel in both directions. We need the details of where you are in the course. The person running your TMS needs to hear that you are considering ketamine, because the two share cautions and the course you are already booked into is theirs to judge.

Bring three things with you: where you are in the course, how many sessions are left, and what has changed so far. The week here is built around ketamine-assisted sessions.

If side effects get stronger once both treatments are running, say it to whoever gives the ketamine and to whoever runs the TMS course, without waiting for the course to end. Stronger side effects are the first thing the 2023 review asks to be monitored and handled (Dębowska and colleagues, 2023).

A record of treatments that did not work is not something we ask you to produce as a condition of coming here. What you have been through is still read: Dr Peter Muscat, a consultant psychiatrist, and Dr Christopher Gauci, an anaesthetist, are the two who read your history, TMS included, at the medical assessment that decides whether the programme fits you, before you pay for it.

On an outpatient route the dose, the therapy and any integration are usually bought separately, from different people, and you are the one who keeps them in step. Here the same team stays with you from the first preparation session to the last integration session. You can read what happens in each of the three phases, and to find out whether the week fits around your TMS course, start with a short form and a call.

Seven weeks, one team

Weeks 1-3 · online

Preparation

Three online sessions with the team who will be with you on the island: what you want from the week, how you live, and how the sessions themselves go.

Week 4 · Malta

Residential week

A medical assessment with the doctor on arrival decides how many ketamine-assisted sessions you have and on which days. A doctor and a nurse are with you through each session. Between sessions, one-to-one therapy and group integration with the other guests. You leave with your integration plan in writing.

Weeks 5-7 · online

Integration

Three online integration sessions with the same team, once you are home.

DetailMaximum four guests. Individual ketamine sessions, group integration with the other guests. How the programme is built

A week in Malta, planned around the treatment you have already had

Tell us where you are in your treatment now, TMS included, and we start with a short call.

No payment and no booking at this step.

Common questions

Is TMS or ketamine better?

Neither has been shown to beat the other. A 2025 analysis of 35 randomised trials and 2,109 people found no significant difference in response or remission between ketamine infusions and TMS, with fewer people dropping out of ketamine, though the authors rated their confidence as very low (Terao and colleagues, PCN Reports, 2025). How the main options for hard-to-treat depression compare goes through the differences. If you are choosing between the two rather than combining them, ask whoever offers you one how they will judge whether it worked, and by when.

What is TMS and ketamine therapy?

It is ketamine and TMS given in one treatment plan, with the magnetic pulses running during the ketamine dose, as two courses across the same weeks, or with ketamine started after a course of TMS. The published experience of it is small and comes mostly from one clinic, so a clinic that offers it should be able to say which form it uses and why. If you are weighing it, a 15-minute call with our team is a place to start.

In short

Ask which of the three forms you are being offered: pulses during the dose, two courses in the same weeks, or ketamine after a course of TMS. They do not carry the same caution: the 2023 review says the two given at separate times may be assumed to remain safe. Treat the combination as early practice rather than settled treatment, and expect the clinic to say so before you agree to it. If you are part-way through a TMS course, say so to the person running it before you add anything, and bring the dates and what changed with you to anyone who offers you ketamine. Our own week in Malta is built around ketamine-assisted sessions, not TMS, and your TMS course is read as part of your history.